Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 401–500 of 3,704
Lupianez‐Merly, C., Dilmaghani, S., Vosoughi, K., & Camilleri, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17856 · Cited by 40
“24 This greater weight loss efficacy is attributed to effects of AOMs on appetite and reg - ulation of food intake.”
BackgroundAlmeida, G. D. O., Nienkotter, T. F., Balieiro, C. C. A., Pasqualotto, E., Cintra, J. B., Carvalho, H. C. P., Silva, A. L. S., Kabariti, J. C., Minucci, B. S., Bertoli, E. D., et al. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00647-3 · Cited by 54
ASN Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases
Ikizler, T. A., Kramer, H., Beddhu, S., Chang, A. R., Friedman, A. N., Harhay, M. N., Jimenez, E. Y., Kistler, B. M., Kukla, A., Larson, K., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000512 · Cited by 44
Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment
d’Aiello, A., Filomia, S., Brecciaroli, M., Sanna, T., Pedicino, D., & Liuzzo, G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01241-3 · Cited by 52
“…on Cardiovascular Outcomes in People with Overweight or Obesity trial) [35] and the SURMOUNT (Tirzepatide Once Weekly for the Treatment of Obesity) [36] trials represent a major step forward in the development of effective treatment options for obese individuals, irrefutably linking inflammation,…”
BackgroundYoshiji, S., Lu, T., Butler‐Laporte, G., Carrasco-Zanini, J., Su, C., Chen, Y., Liang, K., Willett, J., Wang, S., Adra, D., et al. (2023) · Nature Genetics · doi:10.1016/j.cjca.2023.06.321 · Cited by 65
“…such as exercise, appropriate diet or weight-loss drugs such as GLP-1 receptor agonist semaglutide and GLP-1/GIP coagonist tirzepatide, which reduces body fat mass more than lean mass 58,59 , could improve levels of these proteins and subsequently decrease the risk of cardiometabolic diseases.”
Park, J. S., Kim, K. S., & Choi, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0106 · Cited by 60
“Once-weekly administered tirzepatide proved to be both noninferior and superior in reducing glycosylated hemoglobin levels in T2DM patients and demonstrated robust weight loss in obese patients [27,28].”
Prevalence of clinical obesity versus BMI-defined obesity among US adults: a cohort study
Yao, Z., Dardari, Z., Razavi, A. C., Silver, N., Jelwan, Y. A., Erhabor, J., Burka, S., & Blaha, M. J. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00159-7 · Cited by 47
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s003 · Cited by 106
Valenzuela‐Vallejo, L., Guatibonza-García, V., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155248 · Cited by 44
Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lubel, J. S., Hodge, A., & Roberts, S. K. (2023) · Nutrients · doi:10.3390/nu15030687 · Cited by 48
“Similar improvements were seen in the obese non-diabetic group [248], and a substudy of a T2DM tirzepatide trial (SURPASS-3 MRI) [249] showed improvements in liver fat content with tirzepatide compared with insulin.”
BackgroundResultJeon, E., Lee, K. Y., & Kim, K.-K. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23032 · Cited by 39
A critical update on the l eptin‐melanocortin system
Lavoie, O., Michael, N. J., & Caron, A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15765 · Cited by 46
“…satiety, reduce food intake, and reduce body weight, leading to the use of GLP1R agonists for the treatment of obesity (Astrup et al., 2009; Blundell et al., 2017; Flint et al., 1998; Jastreboff et al., 2022; O'Neil et al., 2018; Pratley et al., 2018; Van Can et al., 2014; Verdich et al., 2001).”
BackgroundStenberg, E., & Näslund, E. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01254-z · Cited by 39
“Recently the dual agonist of GLP-1RA/glucose-dependent insulinotropic polypeptide (GIP) (Tirzepatide) has been found to improve glycaemic control and reduce weight in patients with T2D and severe obesity [12] and in patients with severe obesity to reduce weight by up to 20% after a 72 week study period [13].”
BackgroundJiang, Y., Wu, L., Zhu, X., Bian, H., Gao, X., & Xia, M. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02092-2 · Cited by 50
“Vonafexor and structurally optimized FXR agonist, MET409 showed similar reduction [118, 119].”
BackgroundAlsaqaaby, M. S., Cooney, S., le Roux, C. W., & Pournaras, D. J. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00098-6 · Cited by 39
Liu, L., Shi, H., Shi, Y., Wang, A., Guo, N., Tao, H., & Nahata, M. C. (2024) · Pharmaceuticals · doi:10.3390/ph17070828 · Cited by 40
“Tirzepatide, a promising agent that exhibits GLP-1/GIP co-agonism, significantly reduced body weight across all doses in adults with obesity [53,54].”
BackgroundGlucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 48
“However, tirzepa-tide, a dual peptide agonist consisting of both GIP and GLP-1 agonists, has proven valuable in treating both disorders (221).”
Gasoyan, H., Butsch, W. S., Casacchia, N. J., Schulte, R. J., Criswell, V., Fox, J., Renner, H., Le, P. N. B., Alpert, J. M., & Rothberg, M. B. (2025) · Obesity · doi:10.1002/oby.70058 · Cited by 58
Ullah, M. I., & Tamanna, S. (2025) · Medicines · doi:10.3390/medicines12030019 · Cited by 38
“• Efficacy: In the SURMOUNT-1 trial, tirzepatide 15 mg weekly achieved mean weight reductions of 20.9% over 72 weeks, with 50–57% of participants losing ≥ 20% of their body weight [7].”
InfluentialFalk, S., Petersen, J., Svendsen, C., Leguizamón, C. R. R., Jørgensen, S. H., Krauth, N., Ludwig, M. Q., Lundø, K., Roostalu, U., Skovbjerg, G., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112466 · Cited by 41
Szczerbiński, Ł., & Florez, J. C. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00232-2 · Cited by 45
The signaling pathways in obesity‐related complications
Chandrasekaran, P., & Weiskirchen, R. (2024) · Journal of Cell Communication and Signaling · doi:10.1002/ccs3.12039 · Cited by 55
Jensen, M., Sanni, S. J., Riber, D., Holst, J. J., ROSENKILDE, M. M., & Sparre‐Ulrich, A. H. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102006 · Cited by 42
“Interestingly, unimolecular dual agonists of the GLP-1R and GIPR also lead to signi fi cant weight loss in humans, as exempli fi ed by Eli Lilly ’ s tirzepatide [19,20].”
BackgroundInfluentialZisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 48
“Due to its high efficacy in reducing blood glucose levels and improving insulin sensitivity, as well as its well-established safety, metformin is a first-line medical treatment in T2DM patients [186].”
Hropot, T., Herman, R., Janez, A., Lezaic, L., & Jensterle, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108592 · Cited by 39
“However, it has been shown that tirzepatide once weekly is effective in providing a substantial and sustained reduction in body weight in obese persons without diabetes [66].”
BackgroundThe past, present, and future of behavioral obesity treatment
Chao, A. M., Moore, M., & Wadden, T. A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01525-3 · Cited by 40
“Clinical trials have shown that semaglutide produces a mean loss of 14.9% of initial weight at 68 weeks [147] and tirzepatide a reduction of 20.9% at 72 weeks [148].”
InfluentialObesity in the Asia-Pacific Region: Current Perspectives
Lui, D. T. W., Ako, J., Dalal, J. J., Fong, A. Y. Y., Fujino, M., Horton, A., Krittayaphong, R., Almahmeed, W. A., Matthias, A. T., Nelson, A. J., et al. (2024) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2023.68 · Cited by 51
Abdin, A., Böhm, M., Shahim, B., Karlström, P., Kulenthiran, S., Skouri, H. N., & Lund, L. H. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132304 · Cited by 53
A cellular and molecular basis of leptin resistance
Tan, B., Hedbacker, K., Kelly, L., Zhang, Z., Moura‐Assis, A., Luo, J., Rabinowitz, J. D., & Friedman, J. M. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.001 · Cited by 48
GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review
Pantazopoulos, D., Gouveri, E., Papazoglou, D., & Παπάνας, Ν. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112924 · Cited by 53
Billings, L. K., Hsia, S. H., Bays, H. E., Tidemann‐Miller, B., O’Hagan, J., Tham, L. S., Butler, A., KAZDA, C. M., Mather, K. J., & Coşkun, T. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02155-5 · Cited by 47
Wu, H., Yang, W., Guo, T., Cai, X., & Ji, L. (2025) · BMC Medicine · doi:10.1186/s12916-025-04200-0 · Cited by 36
“It was shown that the long-term use of these AOMs in adults contributed to significant weight loss in many studies [10–15].”
Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
Wojtara, M., Mazumder, A., Syeda, Y., & Mozgała, N. (2023) · Advances in Medicine · doi:10.1155/2023/9946924 · Cited by 36
Vuppalanchi, R., Loomba, R. S., Sanyal, A. J., Nikooie, A., Tang, Y., Robins, D. A., Brouwers, B., & Hartman, M. L. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18042 · Cited by 38
Obesity and Weight Loss Strategies for Patients With Heart Failure
Vest, A. R., Schauer, P. R., Rodgers, J. E., Sanderson, E., LaChute, C., Seltz, J., Lavie, C. J., Mandras, S. A., Tang, W. H. W., & daSilva‐deAbreu, A. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.06.006 · Cited by 47
Wharton, S., le Roux, C. W., Kosiborod, M., Platz, E., Brueckmann, M., Jastreboff, A. M., Hussain, S. A., Pedersen, S. D., Borowska, L., Unseld, A., et al. (2024) · Obesity · doi:10.1002/oby.24184 · Cited by 46
Self-citationDuah, J., & Seifer, D. B. (2025) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-024-01339-y · Cited by 54
Effect of Lipidation on the Structure, Oligomerization, and Aggregation of Glucagon-like Peptide 1
Brichtová, E. P., Edu, I. A., Li, X., Becher, F. J., dos Santos, A. L. G., & Jackson, S. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00484 · Cited by 38
Ji, L., Gao, L., Xue, H., Tian, J., Wang, K., Jiang, H., Huang, C., Lian, Q., Yuan, M., Gao, G., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00141-x · Cited by 35
Myasoedova, V. A., Bozzi, M., Valerio, V., Moschetta, D., Massaiu, I., Rusconi, V., Di Napoli, D., Ciccarelli, M., Parisi, V., Agostoni, P., et al. (2023) · Antioxidants · doi:10.3390/antiox13010016 · Cited by 35
Theofilis, P., Vordoni, A., & Kalaitzidis, R. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i39.5691 · Cited by 42
Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
Kreiner, F. F., Schytz, P. A., Heerspink, H. J. L., von Scholten, B. J., & Idorn, T. (2023) · Biomedicines · doi:10.3390/biomedicines11092498 · Cited by 52
Hsu, J. L., & Farrell, T. M. (2023) · The American Surgeon · doi:10.1177/00031348231220576 · Cited by 47
“68,69 Like surgery, these medications can be effective tools for weight loss when coupled with diet and exercise.”
BackgroundObesity management: sex-specific considerations
Kantowski, T., Wiesch, C. S. Z., Aberle, J., & Lautenbach, A. (2024) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-023-07367-0 · Cited by 48
“In the phase 3 SURMOUNT-1 trial, treatment with Tirzepatide once weekly resulted in a mean weight reduction of up to 20.9% over a period of 72 weeks approaching weight loss induced by sleeve gas-trectomy [34].”
BackgroundInfluentialGarvey, W. T., Mahle, C. D., Bell, T., & Kushner, R. F. (2024) · Obesity Science & Practice · doi:10.1002/osp4.756 · Cited by 44
“14,15,17 Through a presumed increase in energy expenditure and by targeting energy intake, novel glucagon receptor/GLP ‐ 1 receptor dual agonists may bridge this gap and elicit more weight loss in people with T2D, or even reduce complications by other pathways (e.g., selective reduction of liver…”
BackgroundA roadmap for clinical trials in MASH-related compensated cirrhosis
Pericàs, J. M., Anstee, Q. M., Augustín, S., Bataller, R. A., Berzigotti, A., Ciudin, A., Francque, S., Abraldeṣ, J. G., Hernández–Gea, V., Pons, M., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00955-8 · Cited by 41
Petersen, K. F., Dufour, S., Mehal, W. Z., & Shulman, G. I. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.07.023 · Cited by 47
Xiao, N., Ding, Y., Cui, B., Li, R., Qu, X.-R., Zhou, H., Au, K.-H., Fan, X.-D., Xie, J.-C., Huang, Y., et al. (2024) · The Innovation Medicine · doi:10.59717/j.xinn-med.2024.100090 · Cited by 43
Self-citationBeyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
Guglielmi, V., Bettini, S., Sbraccia, P., Busetto, L., Pellegrini, M., Yumuk, V., Colao, A. M. L., Ghoch, M. E., & Muscogiuri, G. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00502-7 · Cited by 44
Westermeier, F., & Fisman, E. Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02608-9 · Cited by 45
Gut hormones and appetite regulation
Hong, S.-H., & Choi, K. M. (2024) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000859 · Cited by 35
“The dual-acting GLP-1 and GIP receptor agonist tirzepatide has been reported to be more effective for weight reduction than classical GLP-1R agonists [42,43].”
BackgroundSamuels, J. M., Ye, F., Irlmeier, R., Silver, H., Srivastava, G., & Spann, M. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70004 · Cited by 35
“In addition, challenges with dose titration, crucial for maximizing efficacy as shown in the SURMOUNT and SURPASS trials, 2,20 were evident in our cohort, mirroring findings from other real-world settings.”
New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?
Ryan, D. H. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09967-4 · Cited by 34
“For semaglutide 1 , 74.8%, 54.8%, and 34.8% achieved those, while for tirzepatide [4] it was 90.1%, 78.2% and 62.9%.”
InfluentialDoggrell, S. A. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2206560 · Cited by 34
“Tirzepatide has also been shown to reduce body weight in 2539 subjects living with obesity in a phase 3 placebo-controlled trial [13].”
BackgroundCost-effectiveness analysis of five anti-obesity medications from a US payer's perspective
Gómez Lumbreras, A., Tan, M. S., Villa-Zapata, L., Ilham, S., Earl, J. C., & Malone, D. C. (2023) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.03.012 · Cited by 34
Obesity and atrial fibrillation: Prevalence, pathogenesis, and prognosis
Middeldorp, M. E., Kamsani, S. H., & Sanders, P. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.04.010 · Cited by 42
Richards, J. R., & Khalsa, S. S. (2024) · Obesity Reviews · doi:10.1111/obr.13709 · Cited by 36
“6,7 Newer agents like semaglutide and tirze-patide are showing even more remarkable results — up to 15% 8 and over 20% of total bodyweight, 9 respectively.”
BackgroundObstructive Sleep Apnea, Obesity Hypoventilation Syndrome, and Pulmonary Hypertension
Bjork, S., Jain, D., Hache-Marliere, M., Predescu, S. A., & Mokhlesi, B. (2024) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2024.02.009 · Cited by 40
Stimulating intestinal GIP release reduces food intake and body weight in mice
Lewis, J. E., Nuzzaci, D., James-Okoro, P.-P., Montaner, M., O’Flaherty, E. A. A., Darwish, T., Hayashi, M., Liberles, S. D., Hornigold, D. C., Naylor, J., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101945 · Cited by 39
“Regardless, dual agonists targeting both GLP1R and GIPR decrease body weight and improve glucose tolerance in animal models of obesity and T2D in mice, non-human primates and obese patients with and without T2D [5,16 e 19] with greater ef fi cacy than GLP1R agonism alone.”
BackgroundRochira, V., Greco, C., Boni, S., Costantino, F., Dalla Valentina, L., Zanni, E., Itani, L., & El Ghoch, M. (2024) · Diseases · doi:10.3390/diseases12090204 · Cited by 34
“In detail, the findings on FFM derived from small-sampled trials, specifically three [54,55,58].”
BackgroundMethodResultInfluentialThe promise of tirzepatide: A narrative review of metabolic benefits
Sokary, S., & Bawadi, H. A. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.03.008 · Cited by 44
Liu, C. M., Killion, E. A., Hammoud, R., Lu, S.-C., Komorowski, R., Liu, T., Kanke, M., Thomas, V. A., Cook, K. D., Sivits, G. N., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01295-w · Cited by 44
“This potential is exemplified by the therapeutic efficacy of the dual agonist tirzepatide 14 .”
Karakasis, P., Vlachos, K. G., Antoniadis, A. P., Siontis, K. C., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156463 · Cited by 56
Obesity and hypertension: Obesity medicine association (OMA) clinical practice statement (CPS) 2023
Clayton, T. L., Fitch, A., & Bays, H. E. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100083 · Cited by 50
“[11 – 14, 141, 145, 146]”
Packer, M., Zile, M. R., Kramer, C. M., DiMaria, J. M., Baum, S. J., Litwin, S. E., Murakami, M., Zhou, C., Ou, Y., Koeneman, L., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.06.058 · Cited by 34
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Stefanou, M.-I., Palaiodimou, L., Theodorou, A., Safouris, A., Fischer, U., Kelly, P. J., Dawson, J., Katan, M., Katsanos, A. H., Lambadiari, V., et al. (2024) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864241281903 · Cited by 36
Drastic transformation of visceral adipose tissue and peripheral CD4 T cells in obesity
Shirakawa, K., & Sano, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1044737 · Cited by 38
“With the recent launch of a glucagon-like peptide 1 receptor agonist and dual glucosedependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, long-term maintenance of successful lost weight by medication has finally become feasible (135, 136).”
BackgroundImpact of GLP-1 Agonists on Male Reproductive Health—A Narrative Review
Varnum, A. A., Pozzi, E., Deebel, N. A., Evans, A., Eid, N., Sadeghi‐Nejad, H., & Ramasamy, R. (2023) · Medicina · doi:10.3390/medicina60010050 · Cited by 51
“More recently, the SURMOUNT trial has investigated the potential for tirzepatide as another GLP-1 RA drug to treat individuals with obesity [34].”
BackgroundResultInfluentialCurrent and future state of pharmacological management of pediatric obesity
Fox, C. K., Kelly, A. S., Reilly, J. L., Theis-Mahon, N. R., & Raatz, S. J. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01465-y · Cited by 43
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
MetALD : New Perspectives on an Old Overlooked Disease
Ayares, G., Díaz, L. A., Idalsoaga, F. J., Alkhouri, N., Noureddin, M., Bataller, R. A., Loomba, R. S., Arab, J. P., & Arrese, M. A. (2025) · Liver International · doi:10.1111/liv.70017 · Cited by 40
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 54
“Tirzepatide has established itself as highly effective, with the 15 mg dose achieving 22.5% weight loss (95% CI, − 23.3 to − 21.7), representing a reduction of 23.6 kg (52.0 lb) in phase 3 obesity trials [73,78].”
InfluentialVasdeki, D., Koufakis, T., Tsamos, G., Busetto, L., Zebekakis, P. E., & Kotsa, K. (2022) · Nutrients · doi:10.3390/nu14224801 · Cited by 33
Go Big or Go Home: Obesity and Total Joint Arthroplasty
Blankstein, M., Browne, J. A., Sonn, K. A., Ashkenazi, I., & Schwarzkopf, R. M. (2023) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.07.001 · Cited by 34
Grunstein, R. R., Wadden, T. A., Chapman, J. L., Malhotra, A., & Phillips, C. L. (2023) · SLEEP · doi:10.1093/sleep/zsad224 · Cited by 37
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
Folli, F. B., Finzi, G., Manfrini, R., Galli, A., Casiraghi, F., Centofanti, L., Berra, C., Fiorina, P., Davalli, A. M., Rosa, S. L., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00236.2023 · Cited by 35
A revolution in obesity treatment
Lingvay, I., & Agarwal, S. (2023) · Nature Medicine · doi:10.1038/s41591-023-02538-7 · Cited by 37
Chronic Kidney Disease in the Older Adult Patient with Diabetes
Ravender, R., Roumelioti, M., Schmidt, D. W., Unruh, M. L., & Argyropoulos, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020348 · Cited by 43
“…GLP1-RAs (liraglutide and semaglutide) have been approved as anti-obesity medications even in patients without DM. Dual agonists are associated with more pronounced weight loss [137] and an enhanced antiglycemic effect relative to insulin or pure GLP1-RAs in the SURPASS clinical trial [138–141].”
BackgroundPurnell, J. Q., & le Roux, C. W. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15478 · Cited by 42
“55,56 Likewise, among the currently postulated mechanisms of gastric bypass and sleeve gastrectomy procedures leading to improved appetite control and weight loss include increased meal-related release of several known satiety factors (e.g. peptide YY, GLP-1) and reduction in ghrelin levels.”
BackgroundObstructive sleep apnoea in obesity: A review
Tai, J. E., Phillips, C. L., Yee, B. J., & Grunstein, R. R. (2024) · Clinical Obesity · doi:10.1111/cob.12651 · Cited by 52
“67 These new treatments represent a potential new paradigm in the treatment of OSA, considering the profound degrees of weight loss seen in clinical trials and the known benefits of weight loss in improving OSA.”
BackgroundHeitman, K., Alexander, M. S., & Faul, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105117 · Cited by 50
Chapman, M. B., Norwood, D. A., Price, C., Abdulhadi, B., Kyanam Kabir Baig, K., Ahmed, A. M., Peter, S., Routman, J. S., Sánchez-Luna, S. A., Duggan, E. W., et al. (2024) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.05.012 · Cited by 32
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome
Gajjar, A., Raju, A. K. V., Gajjar, A. J., Menon, M., Shah, S. A. Y., Dani, S. S., & Weinberg, A. M. (2025) · Biomedicines · doi:10.3390/biomedicines13081924 · Cited by 49
“Combination therapy was found to have a greater reduction in weight loss, blood pressure, and HbA1c, likely due to their overlapping mechanisms [51].”
Type 2 Diabetes and the Multifaceted Gut-X Axes
Guo, H., Pan, L.-T., Wu, Q., Wang, L., Huang, Z., Wang, J., Wang, L., Fang, X., Dong, S., Zhu, Y., et al. (2025) · Nutrients · doi:10.3390/nu17162708 · Cited by 44
Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial
SNAITH, J. R., Frampton, R., Samocha‐Bonet, D., & Greenfield, J. R. (2025) · Diabetes Care · doi:10.2337/dc25-2379 · Cited by 51
Alexiadou, K., Hartley, A., Tan, T. M.-M., & Khamis, R. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.03.003 · Cited by 31
Meng, Z., Yang, M., Wen, H., Zhou, S., Chuan, X., & Wang, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1121387 · Cited by 38
“However, some studies believed that the risk still exists (14, 15).”
BackgroundNovel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview
Çaklılı, Ö. T., Cesur, M., Mikhailidis, D. P., & Rizzo, M. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s392684 · Cited by 38
Gourdy, P., Schiele, F., Halimi, J., Kownator, S., Hadjadj, S., & Valensi, P. E. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1227769 · Cited by 36
“5%, with greater improvements than placebo in cardiometabolic risk factors, including waist circumference, systolic and diastolic blood pressure, and fasting insulin, lipid, and aspartate aminotransferase levels (62).”
BackgroundYates, T., Biddle, G. J. H., Henson, J., Edwardson, C. L., Arsenyadis, F., Goff, L. M., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15400 · Cited by 31
“14,15 As such, clinicians have an increasing array of options in the management of obesity, which are likely to become mainstream in clinical practice in coming years.”
BackgroundSingh, S. T., Garg, A., Tantry, U. S., Bliden, K. P., Gurbel, P. A., & Gulati, M. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102403 · Cited by 38
Advances in management of heart failure
Heidenreich, P. A., & Sandhu, A. T. (2024) · BMJ · doi:10.1136/bmj-2023-077025 · Cited by 44
Gogineni, P., Melson, E., Papamargaritis, D., & Davies, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2356254 · Cited by 32
“For example, 72 weeks of treatment with tirzepatide in people with obesity (without diabetes, SURMOUNT-1 trial), resulted in an overall improvement of the total fat mass: total lean mass ratio, but there was a 10.9% reduction of total lean mass at the end of the study [22].”
BackgroundInfluentialChen, L., Chen, X., Ruan, B., Yang, H., & Yu, Y. (2024) · Peptides · doi:10.1016/j.peptides.2024.171245 · Cited by 31
Abbott, S., Adams, B., Agrawal, S., Ahmed, A., Momani, H. A., Al‐Khyatt, W., Al‐Taan, O., Andrews, R. C., Antognozzi, M., Awad, S., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00025-7 · Cited by 52
Wang, M., Chen, X., Liu, Z., Li, Z., Zhu, Z., Liu, S., & Xiao, S. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103385 · Cited by 45
“10 Despite their remarkable benefits, the safety profile of GLP-1RAs has raised increasing concerns, particularly regarding their potential neuropsychiatric effects.”
Wang, L., Wang, Q., Xiong, Y., Shi, W. F., & Xiao, Q. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s540103 · Cited by 46
“In general, the most critical factor for successful obesity treatment is the creation of an energy deficit to reduce excess visceral fat, regardless of the specific dietary or exercise regimen adopted.”
The cardiovascular effects of novel weight loss therapies
Usman, M., Davies, M. J., Hall, M. E., Verma, S., Anker, S. D., Rosenstock, J., & Butler, J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad664 · Cited by 32
Frias, J. P., De Block, C., Brown, K., Wang, H., Thomas, M. K., Zeytinoglu, M., & Maldonado, J. M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae038 · Cited by 40
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.